Regeneron
A topic on our watch list — we track its coverage across 3 domains, including Biotech Pharma, FDA Regulatory Decisions and Psychedelic Medicine.
Coverage of Regeneron is newly on the wire: 13 signals on the latest tracked day, level with its three-week baseline of 13, across 3 domains. That makes it the #292 most-covered of the 337 concerns we track.
If Regeneron matters to your work, it just crossed our flagging thresholds — early and thin history, so watch whether the next few days confirm the move or fade it.
What’s changed
- Sanofi, Regeneron broaden alliance to find their next Dupixent · BioPharma Dive — Latest News · 2026-10-02
- EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses · Clinical Trials Arena · 2026-10-02
- #EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy · Endpoints News · 2026-10-02
- #EASD26: Regeneron sees a future combining its obesity drug with lipid-lowering therapy · Endpoints News · 2026-10-02
- Sanofi builds on immunology alliance with Regeneron for $1B upfront · Endpoints News · 2026-10-01
- STAT+: Sanofi, Regeneron expand partnership after Dupixent success · STAT News — All Content · 2026-10-01
What the reporting says
It shows up alongside FDA (12), Amgen (11), Pfizer (10), Eli Lilly (9), Novartis (9), Abbvie (8), Merck (8), Bristol Myers Squibb (9).
Two steps out: AI (through FDA, 12 shared stories on the weaker link); Cder (through FDA, 12 shared stories on the weaker link); China (through FDA, 12 shared stories on the weaker link); Clinical Trial (through FDA, 12 shared stories on the weaker link).
Tracked since Apr 8, with coverage on 20 separate days — concentrated in Biotech Pharma and Auto.